UK Cost Body Endorses Celgene Blood Cancer Drug

Published: Feb 17, 2011

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (Nasdaq:CELG) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending VIDAZA within its licensed indication, as an option for the treatment of patients in England and Wales with myelodysplastic syndromes (MDS) and acute myeloid leukaemia. NICE determined that VIDAZA, as an innovative, life-extending therapy, is a cost-effective use of National Health Service (NHS) resources.

Back to news